
  
    
      
        Background_NNP
        DNA_NN microarrays_NNS have_VBP proven_VBN very_RB useful_JJ in_IN establishing_VBG
        molecular_JJ definitions_NNS of_IN human_JJ cancer_NN subtypes_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._.
        In_IN some_DT cases_NNS ,_, cancers_NNS that_WDT were_VBD assigned_VBN to_TO a_DT single_JJ
        diagnostic_JJ category_NN by_IN conventional_JJ morphological_JJ
        diagnostic_JJ methods_NNS have_VBP been_VBN found_VBN to_TO have_VB different_JJ gene_NN
        expression_NN profiles_NNS and_CC belong_VB to_TO distinct_JJ molecular_JJ
        subtypes_NNS ._. In_IN particular_JJ ,_, diffuse_NN large_JJ B-_NNP cell_NN lymphoma_NN
        (_( DLBCL_NNP )_) was_VBD shown_VBN to_TO consist_VB of_IN at_IN least_JJS two_CD molecular_JJ
        subtypes_NNS that_WDT differed_VBD in_IN the_DT expression_NN of_IN over_IN several_JJ
        hundred_CD genes_NNS [_NN 1_CD ]_NN ._. Furthermore_RB ,_, patients_NNS with_IN these_DT two_CD
        DLBCL_NNP subtypes_NNS had_VBD strikingly_RB different_JJ long-term_JJ outcomes_NNS
        following_VBG conventional_JJ multi-agent_JJ chemotherapy_NN ._. Patients_NNS
        with_IN germinal_NN center_NN B-_NNP like_IN DLBCL_NNP had_VBD a_DT favorable_JJ
        prognosis_NN ,_, with_IN an_DT apparent_JJ cure_NN rate_NN of_IN 75_CD %_NN ._. On_IN the_DT other_JJ
        hand_NN ,_, patients_NNS with_IN activated_VBN B-_NNP like_IN DLBCL_NNP had_VBD a_DT poor_JJ
        prognosis_NN ,_, with_IN less_JJR than_IN a_DT quarter_NN of_IN these_DT patients_NNS alive_JJ
        five_CD years_NNS following_VBG therapy_NN ._. Therefore_RB ,_, for_IN patients_NNS with_IN
        activated_VBN B-_NNP like_IN DLBCL_NNP ,_, alternative_JJ therapeutic_JJ agents_NNS must_MD
        be_VB identified_VBN ._.
        For_IN this_DT reason_NN ,_, we_PRP have_VBP begun_VBN a_DT survey_NN of_IN novel_NN cancer_NN
        agents_NNS in_IN order_NN to_TO identify_VB drugs_NNS with_IN significant_JJ activity_NN
        against_IN activated_VBN B-_NNP like_IN DLBCL_NNP ._. One_CD drug_NN identified_VBN in_IN this_DT
        screen_NN ,_, flavopiridol_NN ,_, was_VBD found_VBN to_TO be_VB significantly_RB
        cytotoxic_JJ for_IN cell_NN lines_NNS derived_VBN from_IN activated_VBN B-_NNP like_IN
        DLBCL_NNP ._. Flavopiridol_NNP is_VBZ a_DT member_NN of_IN the_DT growing_VBG family_NN of_IN
        cyclin-dependent_JJ kinase_NN (_( CDK_NNP )_) inhibitors_NNS that_WDT have_VBP varying_VBG
        activities_NNS against_IN the_DT multiple_JJ CDK_NNP family_NN members_NNS (_( CDK_NNP 1_CD ,_,
        CDK_NNP 2_CD ,_, CDK_NNP 4_CD ,_, CDK_NNP 6_CD and_CC CDK_NNP 7_CD )_) by_IN competitively_RB blocking_VBG their_PRP$
        ATP-binding_NNP pocket_NN [_NN 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ]_NN ._. In_IN addition_NN to_TO
        arresting_VBG cells_NNS 
        in_IN vitro_NN at_IN the_DT G_NNP 2_CD -_: to-_NN M_NNP and_CC the_DT
        G_NNP 1_CD -_: to-_NN S_NNP transitions_NNS ,_, flavopiridol_NN decreases_VBZ the_DT rate_NN of_IN
        progression_NN through_IN S_NNP phase_NN ._. Since_IN flavopiridol_NN is_VBZ being_VBG
        evaluated_VBN in_IN multiple_JJ cancer_NN clinical_JJ trials_NNS [_NN 7_CD ,_, 9_CD ]_NN ,_, and_CC
        has_VBZ been_VBN shown_VBN to_TO be_VB highly_RB active_JJ in_IN inducing_VBG apoptosis_NNS in_IN
        hematopoietic_JJ neoplasms_NNS [_NN 10_CD ]_NN ,_, we_PRP were_VBD interested_JJ in_IN
        whether_IN flavopiridol_NN might_MD be_VB effective_JJ against_IN activated_VBN
        B-_NNP like_IN DLBCL_NNP ._.
        Although_IN it_PRP is_VBZ clear_JJ that_IN flavopiridol_NN inhibits_NNS CDKs_NNP ,_,
        whether_IN flavopiridol_NN inhibits_NNS other_JJ cellular_JJ targets_NNS is_VBZ not_RB
        known_VBN ._. Recently_RB ,_, flavopiridol_NN was_VBD found_VBN to_TO inhibit_VB the_DT
        activity_NN of_IN a_DT transcription_NN elongation_NN factor_NN P-TEF_NNP b_SYM ,_, a_DT
        complex_NN of_IN cyclins_NNS with_IN CDK_NNP 9_CD [_NN 11_CD ]_NN ._. P-TEF_NNP b_SYM phosphorylates_NNS
        the_DT carboxy-terminal_JJ domain_NN of_IN the_DT RNA_NNP polymerase_NN II_NNP
        complex_JJ [_NN 12_CD ]_NN ,_, facilitating_VBG transcription_NN elongation_NN ._. It_PRP
        was_VBD not_RB known_VBN ,_, however_RB ,_, whether_IN P-TEF_NNP b_SYM regulates_VBZ
        transcriptional_NN elongation_NN of_IN all_DT cellular_JJ genes_NNS or_CC whether_IN
        other_JJ factors_NNS promote_VBP transcriptional_NN elongation_NN on_IN subsets_NNS
        of_IN cellular_JJ genes_NNS ._.
        Using_VBG DNA_NNP microarrays_NNS ,_, we_PRP found_VBD that_DT flavopiridol_NN
        inhibited_VBD gene_NN expression_NN broadly_RB in_IN a_DT manner_NN highly_RB
        related_VBD to_TO other_JJ transcription_NN inhibitors_NNS such_JJ as_IN
        actinomycin_NN D_NNP and_CC
        5_CD ,_, 6_CD -_: dichloro-_NN 1_CD -_: β-_NN D-_NNP ribofuranosyl-benzimidazole_JJ (_( DRB_NNP )_) ._. We_PRP
        were_VBD therefore_RB able_JJ to_TO use_VB flavopiridol_NN to_TO study_VB the_DT
        turnover_NN rate_NN of_IN mRNA_NN on_IN a_DT genomic-scale_JJ ._. mRNA_NN turnover_NN is_VBZ
        regulated_VBN by_IN a_DT variety_NN of_IN cellular_JJ factors_NNS acting_VBG on_IN
        cis-elements_JJ in_IN mRNA_NN molecules_NNS ._. For_IN many_JJ labile_NN mRNAs_NNS ,_,
        adenylate_NN uridylate-rich_JJ elements_NNS (_( AREs_NNP )_) are_VBP required_VBN for_IN
        their_PRP$ rapid_JJ degradation_NN ._. Three_CD different_JJ classes_NNS of_IN ARE_VBP
        have_VBP been_VBN defined_VBN [_NN 13_CD ]_NN ._. A_DT conserved_JJ motif_NN present_JJ in_IN two_CD
        of_IN these_DT classes_NNS ,_, AUUUA_NNP ,_, plays_VBZ an_DT important_JJ role_NN in_IN
        transcript_NN stability_NN for_IN many_JJ cytokines_NNS and_CC early-response_JJ
        genes_NNS (_( ERGs_NNP )_) [_NN 13_CD ]_NN ._. However_RB ,_, there_EX is_VBZ now_RB increasing_VBG
        evidence_NN that_IN other_JJ motifs_NNS may_MD determine_VB the_DT stability_NN of_IN
        transcripts_NNS [_NN 14_CD ]_NN ._.
        By_IN measuring_VBG mRNA_NN turnover_NN rates_NNS comprehensively_RB ,_, we_PRP
        identified_VBD unexpected_JJ relationships_NNS between_IN the_DT function_NN of_IN
        a_DT gene_NN and_CC its_PRP$ mRNA_NN stability_NN ._. In_IN addition_NN ,_, we_PRP found_VBD that_IN
        genes_NNS that_WDT were_VBD transcriptionally_RB inducible_JJ were_VBD
        disproportionately_RB represented_VBN in_IN the_DT class_NN of_IN genes_NNS with_IN
        labile_NN mRNAs_NNS ,_, thus_RB revealing_VBG a_DT coordinated_VBN strategy_NN to_TO
        rapidly_RB modulate_VBP the_DT mRNA_NN levels_NNS of_IN these_DT genes_NNS ._. This_DT
        understanding_NN of_IN mRNA_NN turnover_NN on_IN a_DT genomic_JJ scale_NN provides_VBZ
        fresh_JJ insights_NNS into_IN the_DT effectiveness_NN of_IN flavopiridol_NN as_IN an_DT
        anti-cancer_JJ agent_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        To_TO investigate_VB the_DT effect_NN of_IN flavopiridol_NN treatment_NN on_IN
        activated_VBN B-_NNP like_IN DLBCL_NNP ,_, we_PRP used_VBD cell_NN line_NN OCI-Ly_NNP 3_CD as_IN our_PRP$
        model_NN of_IN activated_VBN B-_NNP like_IN DLBCL_NNP as_IN its_PRP$ gene-expression_JJ
        profile_NN closely_RB resembles_VBZ the_DT profiles_NNS of_IN lymphoma_NN biopsy_NN
        samples_NNS from_IN patients_NNS with_IN this_DT type_NN of_IN DLBCL_NNP [_NN 1_CD ]_NN ._. OCI-Ly_NNP 3_CD
        were_VBD treated_VBN for_IN 3_CD hours_NNS with_IN flavopiridol_NN (_( 1_CD μM_NN )_) and_CC gene_NN
        expression_NN changes_NNS were_VBD monitored_VBN using_VBG Lymphochip_NNP DNA_NNP
        microarrays_NNS [_NN 15_CD ]_NN ._. In_IN comparison_NN to_TO untreated_JJ OCI-Ly_NNP 3_CD
        cells_NNS ,_, flavopiridol_NN treatment_NN decreased_VBD expression_NN of_IN 284_CD
        out_IN of_IN 5_CD ,_, 032_CD microarray_NN elements_NNS (_( 5_CD ._. 64_CD %_NN )_) by_IN at_IN least_JJS
        twofold_NN (_( data_NNS not_RB shown_VBN )_) ._. Similarly_RB ,_, profound_JJ decreases_NNS in_IN
        mRNA_NN levels_NNS were_VBD observed_VBN following_VBG flavopiridol_NN treatment_NN
        of_IN other_JJ lymphoma_NN cell_NN lines_NNS (_( data_NNS not_RB shown_VBN )_) ._. The_DT
        magnitude_NN of_IN the_DT flavopiridol_NN effect_NN on_IN gene_NN expression_NN was_VBD
        related_VBN to_TO the_DT dose_NN of_IN the_DT drug_NN used_VBN (_( Figure_NN 1_CD a_DT )_) ._. We_PRP found_VBD
        that_IN there_EX was_VBD almost_RB no_DT effect_NN on_IN gene_NN expression_NN in_IN cells_NNS
        treated_VBN with_IN 60_CD nM_NN flavopiridol_NN for_IN 1_CD and_CC 3_CD hours_NNS whereas_IN
        300_CD nM_NN flavopiridol_NN induced_VBD broad_JJ changes_NNS in_IN gene_NN
        expression_NN ,_, and_CC 1_CD mM_NN flavopiridol_NN was_VBD yet_RB more_RBR potent_JJ in_IN
        decreasing_VBG mRNA_NN levels_NNS ._. Patients_NNS receiving_VBG infusions_NNS of_IN
        flavopiridol_NN achieve_VBP a_DT biologically_RB active_JJ concentration_NN in_IN
        plasma_NN of_IN 300_CD nM_NN [_NN 16_CD ]_NN ._. To_TO relate_VB these_DT gene_NN expression_NN
        changes_NNS to_TO the_DT biological_JJ activity_NN of_IN flavopiridol_NN ,_, we_PRP
        assayed_JJ the_DT viability_NN of_IN OCI-Ly_NNP 3_CD cells_NNS treated_VBN with_IN
        different_JJ doses_NNS of_IN flavopiridol_NN (_( Figure_NN 1_CD b_SYM )_) ._. Flavopiridol_NNP
        at_IN a_DT concentration_NN of_IN 60_CD nM_NN had_VBD no_DT effect_NN on_IN viability_NN even_RB
        after_IN 48_CD hours_NNS treatment_NN ._. In_IN contrast_NN ,_, 250_CD nM_NN flavopiridol_NN
        decreased_VBD the_DT viability_NN of_IN OCI-Ly_NNP 3_CD cells_NNS at_IN 8_CD hours_NNS ._. Given_VBN
        the_DT similar_JJ dose-response_JJ effects_NNS of_IN flavopiridol_NN on_IN
        cytotoxicity_NN and_CC gene_NN expression_NN ,_, it_PRP is_VBZ likely_JJ that_IN the_DT
        global_JJ reduction_NN in_IN mRNA_NN levels_NNS caused_VBN by_IN flavopiridol_NN is_VBZ a_DT
        major_JJ contributor_NN to_TO its_PRP$ cytotoxic_JJ action_NN ._.
        Flavopiridol_NNP is_VBZ a_DT member_NN of_IN the_DT growing_VBG family_NN of_IN CDK_NNP
        inhibitors_NNS that_WDT have_VBP varying_VBG activities_NNS against_IN the_DT
        multiple_JJ CDK_NNP family_NN members_NNS ._. As_IN most_JJS of_IN the_DT CDK_NNP inhibitors_NNS
        bind_NN to_TO the_DT ATP-binding_NNP pocket_NN of_IN the_DT CDKs_NNP [_NN 17_CD ]_NN ,_, and_CC all_DT
        CDKs_NNP have_VBP similar_JJ ATP-binding_NNP pockets_NNS ,_, it_PRP was_VBD possible_JJ that_IN
        other_JJ CDK_NNP inhibitors_NNS also_RB inhibit_VBP transcription_NN ._. We_PRP
        determined_VBD whether_IN the_DT inhibition_NN of_IN transcription_NN is_VBZ
        specific_JJ to_TO flavopiridol_NN by_IN comparing_VBG gene_NN expression_NN
        profiles_NNS of_IN flavopiridol-treated_JJ cells_NNS with_IN those_DT of_IN cells_NNS
        treated_VBN with_IN the_DT CDK_NNP inhibitors_NNS roscovitine_NN and_CC
        9_CD -_: nitropaullone_NN ._. Roscovitine_NNP is_VBZ a_DT purine_NN derivative_JJ that_IN
        inhibits_NNS CDK_NNP 1_CD ,_, CDK_NNP 2_CD and_CC CDK_NNP 5_CD and_CC blocks_NNS cell-cycle_JJ
        progression_NN both_DT in_IN late_JJ G_NNP 1_CD /_NN early_JJ S_NNP and_CC in_IN M_NNP phase_NN [_NN 18_CD ,_,
        19_CD ,_, 20_CD ,_, 21_CD ]_NN ._. 9_CD -_: nitropaullone_NN ,_, the_DT most_RBS potent_JJ member_NN of_IN a_DT
        novel_NN class_NN of_IN the_DT paullone_NN CDK_NNP inhibitor_NN family_NN ,_, inhibits_NNS
        CDK_NNP 1_CD /_NN cyclin_NN B_NNP at_IN 10_CD -_: fold_VB lower_JJR concentrations_NNS than_IN
        flavopiridol_NN and_CC roscovitine_NN [_NN 22_CD ,_, 23_CD ,_, 24_CD ]_NN ._. As_IN shown_VBN in_IN
        Figure_NN 1_CD c_SYM ,_, the_DT gene_NN expression_NN changes_NNS caused_VBN by_IN
        roscovitine_NN and_CC 9_CD -_: nitropaullone_NN were_VBD different_JJ from_IN those_DT
        of_IN flavopiridol_NN ,_, and_CC only_RB flavopiridol_NN globally_RB reduced_VBD
        mRNA_NN levels_NNS ._.
        To_TO determine_VB whether_IN flavopiridol_NN affects_VBZ transcription_NN
        globally_RB ,_, we_PRP compared_VBD the_DT gene_NN expression_NN profile_NN of_IN
        flavopiridol_NN treatment_NN with_IN the_DT gene_NN expression_NN profiles_NNS
        induced_VBN in_IN OCI-Ly_NNP 3_CD cells_NNS by_IN treatment_NN with_IN two_CD well-studied_JJ
        transcriptional_NN inhibitors_NNS ,_, actinomycin_NN D_NNP and_CC DRB_NNP ._.
        Actinomycin_NNP D_NNP inhibits_NNS transcription_NN initiation_NN broadly_RB by_IN
        intercalating_VBG into_IN DNA_NNP whereas_IN DRB_NNP inhibits_NNS the_DT
        transcription_NN elongation_NN factor_NN P-TEF_NNP b_SYM [_NN 12_CD ]_NN ._. P-TEF_NNP b_SYM is_VBZ a_DT
        complex_NN of_IN cyclins_NNS with_IN CDK_NNP 9_CD ,_, and_CC flavopiridol_NN can_MD also_RB
        inhibit_VB this_DT kinase_NN [_NN 11_CD ]_NN ._. However_RB ,_, it_PRP was_VBD not_RB known_VBN
        whether_IN P-TEF_NNP b_SYM regulates_VBZ transcriptional_NN elongation_NN of_IN all_DT
        cellular_JJ genes_NNS ,_, nor_CC was_VBD it_PRP known_VBN whether_IN flavopiridol_NN would_MD
        inhibit_VB the_DT same_JJ set_NN of_IN genes_NNS as_IN DRB_NNP ._. OCI-Ly_NNP 3_CD cells_NNS were_VBD
        treated_VBN with_IN each_DT inhibitor_NN ,_, and_CC the_DT resultant_JJ changes_NNS in_IN
        gene_NN expression_NN were_VBD found_VBN to_TO be_VB virtually_RB
        indistinguishable_JJ (_( Figure_NN 2_CD a_DT )_) ._. For_IN the_DT majority_NN of_IN
        well-measured_JJ genes_NNS on_IN the_DT Lymphochip_NNP ,_, the_DT mRNA_NN abundance_NN
        decreased_VBD with_IN first-order_JJ kinetics_NNS (_( Figure_NN 3_LS )_) and_CC could_MD
        therefore_RB be_VB used_VBN to_TO measure_VB mRNA_NN turnover_NN rates_NNS (_( see_VB
        Materials_NNPS and_CC methods_NNS )_) ._. Genes_NNP are_VBP grouped_VBN according_VBG to_TO mRNA_NN
        half-life_NN in_IN Figure_NN 2_CD a_DT ._. The_DT turnover_NN rates_NNS of_IN
        representative_NN mRNAs_NNS were_VBD verified_VBN by_IN northern_JJ blot_NN
        analysis_NN in_IN Figure_NN 2_CD band_NN quantitated_JJ in_IN Figure_NN 2_CD c_SYM ._. These_DT
        findings_NNS demonstrate_VBP that_IN all_DT three_CD compounds_NNS behave_VB as_IN
        global_JJ inhibitors_NNS of_IN transcription_NN ,_, and_CC demonstrate_VB that_IN
        P-TEF_NNP b_SYM regulates_VBZ the_DT transcriptional_NN elongation_NN of_IN most_JJS
        cellular_JJ genes_NNS ._. Further_RB ,_, the_DT similar_JJ effects_NNS of_IN
        flavopiridol_NN and_CC DRB_NNP argue_VBP that_IN the_DT predominant_NN effect_NN of_IN
        flavopiridol_NN on_IN gene_NN expression_NN results_NNS from_IN its_PRP$ ability_NN to_TO
        inhibit_VB P-TEF_NNP b_SYM ._.
        To_TO investigate_VB whether_IN the_DT mRNA_NN degradation_NN rates_NNS were_VBD
        first-order_JJ ,_, we_PRP fitted_JJ a_DT linear_JJ regression_NN model_NN for_IN the_DT
        three_CD drugs_NNS for_IN each_DT gene_NN (_( see_VB Materials_NNPS and_CC methods_NNS )_) ._. The_DT
        adjusted_VBN R-_NNP squared_VBD statistic_NN ,_, which_WDT is_VBZ a_DT measure_NN of_IN
        correlation_NN between_IN the_DT observed_VBN data_NN values_NNS and_CC the_DT
        predicted_VBD values_NNS from_IN the_DT linear_JJ model_NN ,_, shows_VBZ how_WRB well_RB a_DT
        first-order_JJ kinetics_NNS model_NN would_MD describe_VB the_DT mRNA_NN
        degradation_NN rates_NNS ._. Figure_NN 3_CD shows_VBZ a_DT histogram_NN of_IN the_DT
        adjusted_VBN R-_NNP squared_VBD statistics_NNS obtained_VBN from_IN fitting_JJ a_DT model_NN
        for_IN each_DT of_IN the_DT 2_CD ,_, 794_CD genes_NNS ._. The_DT median_JJ adjusted_VBN R-_NNP squared_VBD
        was_VBD 0_CD ._. 86_CD ,_, and_CC 79_CD ._. 7_CD %_NN of_IN the_DT genes_NNS had_VBD an_DT adjusted_VBN R-_NNP squared_VBD
        statistic_NN over_IN 0_CD ._. 7_CD ,_, showing_VBG that_IN most_JJS of_IN the_DT genes_NNS had_VBD
        first-order_JJ mRNA_NN degradation_NN rates_NNS ._.
        Given_VBN the_DT demonstration_NN that_DT flavopiridol_NN is_VBZ a_DT global_JJ
        transcriptional_NN inhibitor_NN ,_, we_PRP wished_VBD to_TO understand_VB the_DT
        selective_JJ activity_NN of_IN flavopiridol_NN against_IN certain_JJ cancer_NN
        types_NNS 
        in_IN vivo_NN ._. Clearly_RB ,_, genes_NNS with_IN short_JJ
        mRNA_NN half-lives_JJ would_MD be_VB most_RBS rapidly_RB and_CC quantitatively_RB
        inhibited_VBD by_IN flavopiridol_NN ,_, and_CC thus_RB we_PRP wished_VBD to_TO assign_VB the_DT
        genes_NNS with_IN short_JJ half-lives_JJ in_IN OCI-Ly_NNP 3_CD cells_NNS to_TO functional_JJ
        classes_NNS ._. First_LS ,_, we_PRP searched_VBD for_IN genes_NNS involved_VBN in_IN cellular_JJ
        proliferation_NN that_WDT have_VBP unstable_JJ mRNAs_NNS ,_, as_IN decreased_VBN
        expression_NN of_IN these_DT genes_NNS might_MD provide_VB a_DT mechanism_NN by_IN
        which_WDT flavopiridol_NN preferentially_RB targets_VBZ proliferating_VBG
        cancer_NN cells_NNS ._. Microarray_NNP gene_NN expression_NN analysis_NN can_MD
        readily_RB identify_VB a_DT proliferation_NN '_'' signature_NN '_'' consisting_VBG of_IN
        hundreds_NNS of_IN genes_NNS that_WDT vary_VBP in_IN expression_NN between_IN
        proliferating_VBG and_CC quiescent_JJ cells_NNS [_NN 1_CD ,_, 25_CD ]_NN ._. Genes_NNP can_MD be_VB
        assigned_VBN to_TO the_DT proliferation_NN signature_NN on_IN the_DT basis_NN of_IN
        high_JJ expression_NN in_IN diverse_JJ cell_NN lines_NNS and_CC low_JJ expression_NN in_IN
        chronic_JJ lymphocytic_JJ leukemia_NN (_( CLL_NNP )_) ,_, a_DT malignancy_NN in_IN which_WDT
        the_DT leukemic_JJ cells_NNS are_VBP primarily_RB in_IN G_NNP 0_CD /_NN G_NNP 1_CD phase_NN of_IN the_DT cell_NN
        cycle_NN [_NN 1_CD ]_NN ._. Figure_NN 4_CD apresents_NNS 23_CD genes_NNS with_IN half-lives_JJ of_IN
        less_JJR than_IN 4_CD hours_NNS for_IN which_WDT the_DT average_JJ expression_NN in_IN six_CD
        cell_NN lines_NNS was_VBD fourfold_NN greater_JJR than_IN the_DT average_JJ expression_NN
        in_IN three_CD CLL_NNP samples_NNS ._. This_DT selection_NN criteria_NNS identified_VBD 
        c-myc_JJ ,_, a_DT gene_NN previously_RB known_VBN to_TO
        have_VB a_DT short-lived_JJ mRNA_NN ,_, and_CC an_DT obviously_RB important_JJ target_NN
        of_IN flavopiridol_NN given_VBN its_PRP$ role_NN in_IN G_NNP 1_CD /_NN S_NNP phase_NN progression_NN [_NN
        26_CD ]_NN ._. Interestingly_RB ,_, roughly_RB half_NN of_IN these_DT genes_NNS (_( 11_CD /_NN 23_CD )_) are_VBP
        expressed_VBN preferentially_RB in_IN M_NNP phase_NN and_CC /_NN or_CC encode_NN proteins_NNS
        involved_VBN in_IN M-_NNP phase_NN events_NNS ._. These_DT genes_NNS represent_VBP important_JJ
        targets_NNS of_IN flavopiridol_NN action_NN as_IN they_PRP encode_NN M-_NNP phase_NN
        regulatory_JJ kinases_NNS (_( PLK_NNP ,_, aurora_NN /_NN IPL_NNP 1_CD -_: related_VBN kinase_NN ,_, and_CC
        ckshs_NNS 2_LS )_) ,_, M-_NNP phase_NN checkpoint_NN proteins_NNS (_( CHK_NNP 1_LS )_) ,_, and_CC chromosome_NN
        segregation_NN proteins_NNS (_( CENP-E_NNP ,_, CENP-F_NNP )_) (_( Figure_NN 4_CD a_DT )_) ._. Given_VBN
        the_DT relatively_RB short_JJ duration_NN of_IN M_NNP phase_NN in_IN most_JJS cells_NNS ,_, the_DT
        short_JJ half-lives_JJ of_IN these_DT mRNAs_NNS may_MD be_VB important_JJ to_TO ensure_VB
        that_IN key_JJ M-_NNP phase_NN regulators_NNS are_VBP not_RB expressed_VBN as_IN the_DT cell_NN
        progresses_VBZ from_IN M_NNP to_TO G_NNP 1_CD phase_NN ._.
        Another_DT important_JJ class_NN of_IN genes_NNS that_WDT might_MD contribute_VB
        to_TO the_DT efficacy_NN of_IN flavopiridol_NN would_MD include_VB
        anti-apoptotic_JJ genes_NNS with_IN rapid_JJ mRNA_NN turnover_NN (_( Figure_NN 4_CD b_SYM )_) ._.
        Two_CD anti-apoptotic_JJ Bcl-_NNP 2_CD family_NN members_NNS that_WDT were_VBD expressed_VBN
        in_IN OCI-Ly_NNP 3_CD cells_NNS -_: A_DT 1_CD and_CC MCL_NNP 1_CD -_: had_VBD mRNA_NN half-lives_JJ
        shorter_JJR than_IN 3_CD hours_NNS ._. Three_CD members_NNS of_IN the_DT IAP_NNP family_NN (_( 
        c-_NN IAP_NNP 1_CD ,_, c-_NN IAP_NNP 2_CD ,_, NAIP_NNP )_) had_VBD very_RB short_JJ
        mRNA_NN half-lives_JJ and_CC encode_NN anti-apoptotic_JJ proteins_NNS that_WDT act_NN
        by_IN directly_RB binding_JJ to_TO caspases_NNS 3_CD ,_, 7_CD ,_, and_CC 9_CD [_NN 27_CD ]_NN ._. The_DT NF-κ_NNP
        B_NNP target_NN gene_NN 
        A_DT 20_CD ,_, an_DT inhibitor_NN of_IN tumor_NN necrosis_NNS
        factor_NN (_( TNF_NNP )_) -_: induced_VBN apoptosis_NNS [_NN 28_CD ]_NN ,_, is_VBZ expressed_VBN in_IN
        OCI-Ly_NNP 3_CD cells_NNS and_CC had_VBD a_DT very_RB short_JJ mRNA_NN half-life_NN ._. As_IN TNF-α_NNP
        is_VBZ expressed_VBN by_IN OCI-Ly_NNP 3_CD cells_NNS ,_, inhibition_NN of_IN A_DT 20_CD expression_NN
        by_IN flavopiridol_NN treatment_NN may_MD contribute_VB to_TO its_PRP$ cytotoxic_JJ
        effect_NN on_IN these_DT cells_NNS ._. In_IN accord_NN with_IN these_DT results_NNS ,_,
        flavopiridol_NN treatment_NN was_VBD recently_RB shown_VBN to_TO downregulate_NN
        two_CD of_IN these_DT anti-apoptotic_JJ proteins_NNS ,_, MCL_NNP 1_CD and_CC Bag-_NNP 1_CD ,_, and_CC
        induce_VB apoptosis_NNS in_IN B-CLL_NNP cells_NNS treated_VBN with_IN flavopiridol_NN [_NN
        29_CD ]_NN ._.
        The_DT majority_NN of_IN the_DT genes_NNS with_IN labile_NN mRNAs_NNS ,_, however_RB ,_,
        did_VBD not_RB fall_VB into_IN the_DT cell_NN cycle_NN or_CC apoptosis_NNS categories_NNS
        but_CC instead_RB included_VBD many_JJ genes_NNS that_WDT are_VBP known_VBN to_TO be_VB
        inducible_JJ by_IN cellular_JJ signaling_VBG ._. For_IN example_NN ,_, transcription_NN
        factors_NNS belonging_VBG to_TO the_DT NF-κB_NNP family_NN are_VBP activated_VBN by_IN a_DT
        wide_JJ variety_NN of_IN cellular_JJ signaling_VBG events_NNS ,_, and_CC several_JJ
        known_VBN NF-κB_NNP target_NN genes_NNS (_( 
        A_DT 1_CD ,_, A_DT 20_CD ,_, c-_NN IAP_NNP 1_CD ,_, c-_NN IAP_NNP 2_CD ,_, IκB_NNP alpha_NN ,_, IκB_NNP
        epsilon_NN ,_, CD_NNP 54_CD ,_, IL-_NNP 6_CD ,_, IL-_NNP 8_CD ,_, TNF-α_NNP ,_, IRF-_NNP 4_LS )_) were_VBD found_VBN to_TO
        have_VB unstable_JJ mRNAs_NNS (_( Figure_NN 4_CD d_SYM )_) ._. This_DT observation_NN led_VBD us_PRP to_TO
        investigate_VB the_DT possibility_NN that_IN the_DT class_NN of_IN genes_NNS that_WDT
        are_VBP transcriptionally_RB induced_VBN by_IN cellular_JJ signaling_VBG events_NNS
        is_VBZ enriched_JJ for_IN genes_NNS with_IN labile_NN mRNAs_NNS ._. We_PRP used_VBD Lymphochip_NNP
        microarrays_NNS to_TO profile_VB the_DT changes_NNS in_IN gene_NN expression_NN that_WDT
        occurred_VBD in_IN response_NN to_TO a_DT wide_JJ variety_NN of_IN signaling_VBG events_NNS :_:
        B-_NNP cell_NN lymphoma_NN cell_NN lines_NNS stimulated_VBN by_IN crosslinking_VBG the_DT
        B-_NNP cell_NN antigen_NN receptor_NN or_CC by_IN treatment_NN with_IN phorbol_NN ester_NN
        and_CC ionomycin_NN (_( PI_NNP )_) ,_, resting_VBG peripheral_JJ blood_NN T_NN cells_NNS
        stimulated_VBN with_IN PI_NNP ,_, and_CC peripheral_JJ blood_NN monocytes_NNS
        stimulated_VBN with_IN lipopolysaccharide_NN ._. Figure_NN 4_CD dshows_NNS genes_NNS
        with_IN relatively_RB short_JJ mRNA_NN half-lives_JJ (_( <_NN 2_CD hours_NNS and_CC 2_CD -_: 4_CD
        hours_NNS )_) that_WDT were_VBD also_RB transcriptionally_RB induced_VBN at_IN least_JJS
        threefold_RB in_IN one_CD of_IN the_DT cellular_JJ activation_NN experiments_NNS
        described_VBD above_IN ._. Roughly_RB one_CD third_NN of_IN the_DT inducible_JJ genes_NNS
        in_IN OCI-Ly_NNP 3_CD cells_NNS were_VBD in_IN this_DT rapid_JJ mRNA_NN turnover_NN category_NN
        (_( Figure_NN 4_CD c_SYM )_) ._. By_IN contrast_NN ,_, 16_CD ._. 8_CD %_NN of_IN the_DT genes_NNS that_WDT were_VBD not_RB
        induced_VBN by_IN these_DT stimuli_NNS had_VBD mRNA_NN half-lives_JJ of_IN less_JJR than_IN 4_CD
        hours_NNS (_( 
        P_NN <_NN 0_CD ._. 001_CD )_) ._.
        This_DT analysis_NN of_IN mRNA_NN turnover_NN in_IN OCI-Ly_NNP 3_CD cells_NNS
        therefore_RB suggested_VBD that_IN transcriptionally_RB inducible_JJ genes_NNS
        are_VBP ,_, as_IN a_DT class_NN ,_, likely_JJ to_TO generate_VB labile_NN mRNAs_NNS ._. To_TO test_VB
        this_DT notion_NN ,_, we_PRP profiled_VBN mRNA_NN turnover_NN rates_NNS in_IN peripheral_JJ
        blood_NN mononuclear_NN cells_NNS (_( PBMCs_NNP )_) after_IN stimulation_NN with_IN PI_NNP ._.
        PBMCs_NNP were_VBD stimulated_VBN with_IN PI_NNP for_IN 3_CD hours_NNS ,_, at_IN which_WDT time_NN
        flavopiridol_NN was_VBD added_VBN and_CC mRNA_NN levels_NNS were_VBD subsequently_RB
        determined_VBN by_IN microarray_NN analysis_NN ._. Genes_NNP were_VBD assigned_VBN to_TO
        the_DT inducible_JJ class_NN if_IN their_PRP$ mRNA_NN levels_NNS increased_VBN more_JJR
        than_IN fourfold_NN by_IN PI_NNP in_IN 3_CD hours_NNS ._. As_IN shown_VBN in_IN Figure_NN 5_CD a_DT ,_, a_DT
        substantial_JJ proportion_NN (_( 44_CD %_NN )_) of_IN the_DT inducible_JJ genes_NNS had_VBD
        mRNA_NN half-lives_JJ shorter_JJR than_IN 2_CD hours_NNS ._. By_IN contrast_NN ,_, only_RB 11_CD %_NN
        of_IN the_DT non-inducible_JJ class_NN of_IN genes_NNS had_VBD mRNA_NN half-lives_JJ
        less_JJR than_IN 2_CD hours_NNS ,_, and_CC more_JJR than_IN 70_CD %_NN of_IN these_DT genes_NNS had_VBD
        mRNA_NN half-lives_JJ longer_JJR than_IN 6_CD hours_NNS (_( 
        P_NN <_NN 0_CD ._. 001_CD )_) (_( Figure_NN 5_CD a_DT )_) ._. This_DT
        result_NN confirmed_VBD ,_, in_IN an_DT independent_JJ cellular_JJ system_NN ,_, the_DT
        observation_NN that_IN transcriptionally_RB inducible_JJ genes_NNS
        preferentially_RB encode_NN rapidly_RB degraded_JJ mRNAs_NNS ._.
        We_PRP next_RB investigated_VBD the_DT functional_JJ characteristics_NNS of_IN
        the_DT genes_NNS assigned_VBN to_TO each_DT mRNA_NN turnover_NN class_NN (_( Figure_NN 5_CD b_SYM )_) ._.
        More_JJR than_IN one_CD third_NN of_IN genes_NNS regulating_VBG apoptosis_NNS were_VBD both_DT
        inducible_JJ and_CC had_VBD mRNA_NN half-lives_JJ of_IN less_JJR than_IN 2_CD hours_NNS ._. By_IN
        contrast_NN ,_, only_RB 10_CD %_NN of_IN the_DT genes_NNS encoding_VBG cell-surface_JJ
        proteins_NNS were_VBD in_IN this_DT class_NN ._. The_DT apoptosis_NNS regulators_NNS
        included_VBD several_JJ anti-apoptotic_JJ genes_NNS discussed_VBN previously_RB
        (_( 
        A_DT 20_CD ,_, MCL_NNP 1_CD ,_, c-_NN IAP_NNP 2_LS )_) ,_, as_RB well_RB as_RB
        potentially_RB pro-apoptotic_JJ genes_NNS such_JJ as_IN those_DT for_IN Fas_NNP
        ligand_NN and_CC TNF_NNP receptor_NN type_NN II_NNP ._. PHLDA_NNP 1_CD is_VBZ the_DT human_JJ
        homolog_NN of_IN TDAG_NNP 51_CD ,_, a_DT pleckstrin-homology_JJ domain_NN protein_NN
        that_WDT may_MD modulate_VBP apoptosis_NNS by_IN regulating_VBG Fas_NNP ligand_NN
        expression_NN following_VBG stimulation_NN through_IN the_DT T-_NNP cell_NN
        receptor_NN ._. It_PRP is_VBZ well_RB known_VBN that_IN apoptosis_NNS in_IN T_NN lymphocytes_NNS
        is_VBZ an_DT elaborately_RB orchestrated_VBN process_NN following_VBG lymphocyte_NN
        activation_NN that_WDT allows_VBZ clonal_NN expansion_NN of_IN the_DT activated_VBN T_NN
        cells_NNS while_IN eventually_RB eliminating_VBG the_DT clone_NN through_IN the_DT
        process_NN of_IN activation-induced_JJ cell_NN death_NN [_NN 30_CD ]_NN ._. Thus_RB ,_,
        anti-apoptotic_JJ gene_NN products_NNS are_VBP required_VBN early_RB during_IN
        lymphocyte_NN activation_NN ,_, whereas_IN attenuation_NN of_IN the_DT clonal_NN
        burst_NN eventually_RB requires_VBZ pro-apoptotic_JJ signaling_VBG through_IN
        Fas_NNP and_CC the_DT TNF_NNP receptors_NNS ._. This_DT change_NN in_IN apoptotic_JJ
        responsiveness_NNS may_MD be_VB accomplished_VBN rapidly_RB by_IN combining_VBG
        transcriptional_NN regulation_NN with_IN rapid_JJ mRNA_NN turnover_NN of_IN key_JJ
        apoptosis-regulatory_JJ genes_NNS ._.
        Transcriptional_NNP reprogramming_VBG following_VBG lymphocyte_NN
        activation_NN involves_VBZ the_DT coordinate_VB induction_NN of_IN
        transcription_NN factors_NNS [_NN 31_CD ]_NN and_CC many_JJ of_IN these_DT were_VBD found_VBN to_TO
        have_VB labile_NN mRNAs_NNS (_( Figure_NN 5_CD b_SYM )_) ._. Several_JJ of_IN these_DT genes_NNS are_VBP
        known_VBN to_TO encode_NN immediate_JJ early_JJ transcription_NN factors_NNS (_( for_IN
        example_NN ,_, FosB_NNP ,_, NAB_NNP 2_CD ,_, ATF-_NNP 3_CD ,_, NOT_NNP 1_LS )_) that_WDT are_VBP induced_VBN by_IN a_DT
        wide_JJ range_NN of_IN cellular_JJ stimuli_NNS ,_, and_CC this_DT class_NN of_IN
        transcription_NN factors_NNS is_VBZ well_RB known_VBN to_TO have_VB unstable_JJ mRNAs_NNS
        [_NN 32_CD ]_NN ._. Other_JJ inducible_JJ transcription_NN factors_NNS with_IN labile_NN
        mRNAs_NNS have_VBP more_RBR lymphocyte-specific_JJ functions_NNS ,_, such_JJ as_IN
        IRF-_NNP 4_CD ,_, a_DT factor_NN that_WDT is_VBZ required_VBN for_IN lymphocyte_NN activation_NN
        but_CC is_VBZ not_RB required_VBN in_IN other_JJ lineages_NNS [_NN 33_CD ]_NN ._.
        Not_RB surprisingly_RB ,_, the_DT most_RBS inducible_JJ class_NN of_IN genes_NNS in_IN
        PBMCs_NNP encoded_JJ cytokines_NNS ,_, chemokines_NNS and_CC their_PRP$ receptors_NNS
        (_( Figure_NN 5_CD c_SYM )_) ._. Within_IN this_DT class_NN ,_, more_JJR than_IN 25_CD %_NN of_IN genes_NNS had_VBD
        mRNA_NN half-lives_JJ of_IN less_JJR than_IN 2_CD hours_NNS ._. As_IN expected_VBN ,_, many_JJ
        cytokine_NN mRNAs_NNS were_VBD both_DT rapidly_RB inducible_JJ and_CC rapidly_RB
        degraded_JJ (_( Figure_NN 5_CD d_SYM )_) ._. Unexpectedly_NNP ,_, the_DT chemokine_NN genes_NNS had_VBD
        much_RB more_RBR stable_JJ mRNAs_NNS than_IN the_DT cytokine_NN genes_NNS ,_, even_RB though_IN
        they_PRP were_VBD strongly_RB induced_VBN by_IN PI_NNP treatment_NN (_( Figure_NN 5_CD d_SYM )_) ._. The_DT
        mRNAs_NNS for_IN the_DT cytokine_NN and_CC chemokine_NN receptors_NNS also_RB
        differed_VBD in_IN their_PRP$ stability_NN ._. The_DT inducible_JJ chemokine_NN
        receptors_NNS CCR_NNP 1_CD and_CC CXCR_NNP 5_CD had_VBD labile_NN mRNAs_NNS ,_, whereas_IN most_JJS of_IN
        the_DT inducible_JJ cytokine_NN receptors_NNS (_( IL-_NNP 2_CD ,_, IL-_NNP 3_CD ,_, IL-_NNP 6_CD receptor_NN
        α_NN chains_NNS )_) had_VBD relatively_RB stable_JJ mRNAs_NNS ._. The_DT differential_NN
        mRNA_NN stabilities_NNS of_IN cytokines_NNS ,_, chemokines_NNS and_CC their_PRP$
        receptors_NNS reflect_VBP their_PRP$ divergent_JJ biological_JJ functions_NNS ._.
        Cytokines_NNP potently_RB induce_VB activation_NN and_CC differentiation_NN of_IN
        target_NN cells_NNS in_IN a_DT tightly_RB regulated_VBN temporal_JJ fashion_NN during_IN
        immune_JJ responses_NNS [_NN 34_CD ]_NN ._. To_TO limit_VB inappropriate_JJ effects_NNS of_IN
        cytokines_NNS both_DT temporally_RB and_CC spatially_RB on_IN bystander_NN cells_NNS ,_,
        the_DT levels_NNS of_IN these_DT factors_NNS must_MD be_VB modulated_JJ rapidly_RB ,_,
        which_WDT can_MD be_VB achieved_VBN given_VBN their_PRP$ short_JJ mRNA_NN half-lives_JJ ._. On_IN
        the_DT other_JJ hand_NN ,_, chemokines_NNS are_VBP chemoattractants_NNS that_WDT signal_NN
        leukocyte_NN migration_NN by_IN setting_VBG up_RP concentration_NN gradients_NNS
        that_WDT are_VBP recognized_VBN by_IN chemokine_NN receptors_NNS [_NN 35_CD ]_NN ._. The_DT
        inducible_JJ chemokines_NNS are_VBP used_VBN in_IN inflammatory_JJ responses_NNS and_CC
        wound_VBD healing_VBG to_TO attract_VB the_DT appropriate_JJ complement_VB of_IN
        immune_JJ cells_NNS to_TO the_DT affected_VBN tissues_NNS ._. These_DT cellular_JJ
        reactions_NNS need_VBP to_TO be_VB rapidly_RB initiated_VBN but_CC are_VBP slowly_RB
        resolved_VBN ,_, a_DT kinetic_JJ profile_NN that_WDT can_MD be_VB understood_VBN in_IN light_NN
        of_IN the_DT relative_JJ stability_NN of_IN chemokine_NN mRNAs_NNS ._.
        Finally_RB ,_, we_PRP investigated_VBD whether_IN known_VBN 
        cis_NNS -_: acting_VBG mRNA_NN motifs_NNS could_MD account_VB
        for_IN the_DT mRNA_NN turnover_NN rates_NNS measured_VBN in_IN the_DT present_JJ study_NN ._.
        Adenylate-uridylate-rich_NNP elements_NNS (_( AREs_NNP )_) mediate_VB rapid_JJ
        turnover_NN of_IN some_DT mRNAs_NNS ._. Three_CD different_JJ classes_NNS of_IN ARE_VBP have_VBP
        been_VBN defined_VBN ,_, two_CD of_IN which_WDT include_VBP the_DT core_NN motif_NN AUUUA_NNP [_NN
        13_CD ]_NN ._. A_DT recent_JJ bioinformatics_NNS analysis_NN of_IN labile_NN mRNAs_NNS with_IN
        AUUUA_NNP motifs_NNS extended_VBD this_DT core_NN motif_NN to_TO the_DT nonamer_NN
        UAUUUAWW_NNP ,_, and_CC a_DT database_NN of_IN mRNAs_NNS that_WDT have_VBP matches_VBZ to_TO this_DT
        motif_NN in_IN their_PRP$ 3_CD '_POS untranslated_JJ regions_NNS was_VBD created_VBN [_NN 36_CD ]_NN ._.
        Using_VBG this_DT database_NN ,_, we_PRP examined_VBD the_DT distribution_NN of_IN these_DT
        AU-rich_NNP motifs_NNS among_IN the_DT classes_NNS of_IN mRNAs_NNS with_IN different_JJ
        half-lives_JJ ._. Figure_NN 6_CD shows_VBZ that_IN this_DT motif_NN was_VBD found_VBN
        preferentially_RB in_IN the_DT most_RBS unstable_JJ mRNAs_NNS and_CC was_VBD observed_VBN
        with_IN decreasing_VBG frequency_NN in_IN mRNAs_NNS with_IN longer_RBR half-lives_JJ ._.
        Nonetheless_RB ,_, 10_CD %_NN of_IN the_DT genes_NNS in_IN the_DT long_JJ half-life_NN
        category_NN (_( >_NN 8_CD hours_NNS )_) contained_VBD AREs_NNP ,_, demonstrating_VBG that_IN
        the_DT ARE_VBP motif_NN is_VBZ not_RB completely_RB predictive_JJ of_IN rapid_JJ mRNA_NN
        turnover_NN ._. Furthermore_RB ,_, many_JJ of_IN the_DT RNAs_NNP with_IN unstable_JJ mRNAs_NNS
        lacked_VBD the_DT ARE_VBP consensus_NN motif_NN ,_, suggesting_VBG that_IN other_JJ 
        cis_NNS -_: elements_NNS may_MD be_VB responsible_JJ for_IN
        their_PRP$ rapid_JJ degradation_NN ._.
      
      
        Conclusions_NNP
        The_DT systematic_JJ determination_NN of_IN mRNA_NN degradation_NN rates_NNS
        described_VBD in_IN the_DT present_JJ report_NN revealed_VBD an_DT underlying_VBG
        logic_NN that_WDT relates_VBZ gene_NN function_NN and_CC mRNA_NN stability_NN ._. The_DT
        largest_JJS category_NN of_IN genes_NNS found_VBD to_TO have_VB unstable_JJ mRNAs_NNS
        included_VBD genes_NNS that_WDT were_VBD inducible_JJ by_IN various_JJ cellular_JJ
        signaling_VBG events_NNS ._. The_DT inducibility_NN of_IN many_JJ of_IN these_DT genes_NNS
        is_VBZ known_VBN to_TO be_VB due_JJ to_TO transcriptional_NN activation_NN of_IN their_PRP$
        promoters_NNS ._. Thus_RB ,_, the_DT rapid_JJ degradation_NN of_IN these_DT mRNAs_NNS
        allows_VBZ their_PRP$ levels_NNS to_TO rapidly_RB drop_VB when_WRB transcriptional_NN
        activation_NN is_VBZ terminated_VBN ._. By_IN categorizing_VBG genes_NNS using_VBG the_DT
        functional_JJ properties_NNS of_IN their_PRP$ encoded_JJ proteins_NNS ,_, we_PRP found_VBD
        that_IN certain_JJ functional_JJ classes_NNS were_VBD relatively_RB enriched_JJ
        for_IN unstable_JJ mRNAs_NNS ._. Two_CD such_JJ classes_NNS ,_, the_DT cytokine_NN genes_NNS
        and_CC immediate_JJ early_JJ transcription_NN factor_NN genes_NNS ,_, were_VBD
        previously_RB known_VBN to_TO have_VB unstable_JJ mRNAs_NNS ._. The_DT class_NN of_IN
        apoptosis_NNS regulators_NNS ,_, however_RB ,_, was_VBD not_RB previously_RB known_VBN to_TO
        be_VB enriched_JJ for_IN labile_NN mRNAs_NNS ._. However_RB ,_, given_VBN the_DT need_NN to_TO
        rapidly_RB modulate_VBP apoptosis_NNS during_IN development_NN ,_, cellular_JJ
        differentiation_NN ,_, and_CC immune_JJ responses_NNS ,_, this_DT property_NN of_IN the_DT
        apoptotic_JJ genes_NNS can_MD be_VB readily_RB understood_VBN ._. Another_DT
        unanticipated_JJ finding_NN was_VBD that_IN many_JJ critical_JJ regulators_NNS of_IN
        M_NNP phase_NN of_IN the_DT cell_NN cycle_NN had_VBD rapidly_RB degraded_JJ mRNAs_NNS ._. In_IN
        light_NN of_IN the_DT short_JJ duration_NN of_IN M_NNP phase_NN ,_, these_DT labile_NN
        M-_NNP phase_NN regulators_NNS may_MD need_VB to_TO be_VB eliminated_VBN rapidly_RB to_TO
        allow_VB correct_JJ entry_NN into_IN G_NNP 1_CD phase_NN of_IN the_DT cell_NN cycle_NN ._.
        The_DT initial_JJ impetus_NN of_IN this_DT research_NN was_VBD to_TO understand_VB
        the_DT mechanism_NN of_IN action_NN of_IN the_DT anti-cancer_JJ drug_NN
        flavopiridol_NN ._. The_DT regulatory_JJ logic_NN of_IN mRNA_NN degradation_NN
        revealed_VBD in_IN this_DT study_NN gives_VBZ us_PRP insight_NN into_IN how_WRB this_DT
        general_JJ transcriptional_NN inhibitor_NN can_MD have_VB selective_JJ
        toxicity_NN for_IN tumor_NN cells_NNS ._. In_IN particular_JJ ,_, the_DT short_JJ
        half-lives_JJ of_IN mRNAs_NNS encoding_VBG M-_NNP phase_NN proteins_NNS and_CC other_JJ key_JJ
        cell-cycle_JJ regulators_NNS (_( for_IN example_NN ,_, c-_NN Myc_NNP )_) may_MD contribute_VB
        to_TO the_DT cytotoxicity_NN of_IN flavopiridol_NN for_IN cancer_NN cells_NNS but_CC
        may_MD also_RB contribute_VB to_TO the_DT dose-limiting_JJ toxicity_NN of_IN
        flavopiridol_NN for_IN gut_NN epithelium_NN ,_, leading_VBG to_TO secretory_NN
        diarrhea_NN [_NN 16_CD ]_NN ._. However_RB ,_, the_DT present_JJ results_NNS also_RB suggest_VBP
        that_DT flavopiridol_NN may_MD be_VB more_RBR effective_JJ in_IN treating_VBG certain_JJ
        types_NNS of_IN cancer_NN cells_NNS that_WDT are_VBP highly_RB dependent_JJ on_IN genes_NNS
        with_IN unstable_JJ mRNAs_NNS ._. For_IN example_NN ,_, OCI-Ly_NNP 3_CD lymphoma_NN cells_NNS
        constitutively_RB express_VBP two_CD anti-apoptotic_JJ BCL-_NNP 2_CD family_NN
        members_NNS ,_, A_DT 1_CD and_CC MCL_NNP 1_CD ,_, which_WDT are_VBP not_RB expressed_VBN at_IN high_JJ
        levels_NNS in_IN normal_JJ lymphocytes_NNS ._. The_DT instability_NN of_IN the_DT A_DT 1_CD and_CC
        MCL_NNP 1_CD mRNAs_NNS therefore_RB may_MD contribute_VB to_TO the_DT toxicity_NN of_IN
        flavopiridol_NN for_IN these_DT lymphoma_NN cells_NNS ._. Gene_NNP expression_NN
        profiling_VBG demonstrated_VBN that_IN the_DT OCI-Ly_NNP 3_CD cell_NN line_NN is_VBZ an_DT
        excellent_JJ model_NN for_IN the_DT activated_VBN B-_NNP like_IN DLBCL_NNP subtype_NN [_NN
        1_CD ]_NN ._. Indeed_RB ,_, fresh_JJ lymphoma_NN biopsies_NNS from_IN such_JJ patients_NNS
        revealed_VBD high_JJ expression_NN of_IN A_DT 1_CD and_CC MCL_NNP 1_CD in_IN most_JJS cases_NNS [_NN 1_CD ]_NN ._.
        These_DT results_NNS suggest_VBP that_WDT activated_VBN B-_NNP like_IN DLBCL_NNP might_MD be_VB
        a_DT particularly_RB attractive_JJ candidate_NN disease_NN for_IN new_JJ
        clinical_JJ trials_NNS of_IN flavopiridol_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Chemicals_NNS and_CC cells_NNS
          Flavopiridol_NNP and_CC 9_CD -_: nitropaullone_NN were_VBD obtained_VBN from_IN
          the_DT NCI_NNP Developmental_NNP Therapeutics_NNP Program_NNP ._. DRB_NNP ,_, MTT_NNP
          (_( 3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazol-_NN 2_CD -_: yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyltetrazolium_NN
          bromide_NN )_) and_CC ionomycin_NN were_VBD purchased_VBN from_IN Sigma_NNP ._.
          Actinomycin_NNP D_NNP ,_, roscovitine_NN ,_, phorbol_NN ester_NN and_CC
          lipopolysaccharide_NN (_( LPS_NNP )_) were_VBD purchased_VBN from_IN Calbiochem_NNP ._.
          Anti-human_NNP IgM_NNP was_VBD purchased_VBN from_IN Jackson_NNP ImmunoResearch_NNP
          Laboratories_NNPS ,_, Inc_NNP ._.
          Primary_JJ T_NN cells_NNS and_CC monocytes_NNS were_VBD purified_JJ from_IN human_JJ
          blood_NN by_IN magnetic_JJ cell_NN sorting_VBG ._. PBMCs_NNP were_VBD purified_JJ by_IN
          Ficoll_NNP density_NN gradient_NN centrifugation_NN ._. OCI-Ly_NNP 1_CD and_CC
          OCI-Ly_NNP 3_CD were_VBD maintained_VBN in_IN Iscove_NNP 's_POS modified_VBN essential_JJ
          medium_NN with_IN β-mercaptoethanol_JJ (_( 55_CD μM_NN )_) ,_, penicillin_NN (_( 50_CD
          units_NNS /_NN ml_NN )_) ,_, streptomycin_NN (_( 50_CD μg_NN /_NN ml_NN )_) ,_, and_CC 20_CD %_NN heparinized_JJ
          normal_JJ human_JJ plasma_NN ._. SUDHL-_NNP 5_CD ,_, SUDHL-_NNP 6_CD ,_, WSU-_NNP 1_CD ,_, Jurkat_NNP ,_,
          MCF-_NNP 7_CD ,_, PC_NN 3_CD ,_, BJAB_NNP ,_, T_NN cells_NNS ,_, monocytes_NNS and_CC PBMCs_NNP were_VBD
          maintained_VBN in_IN RPMI_NNP 1640_CD medium_NN with_IN L-_NNP glutamine_NN ,_, HEPES_NNP ,_,
          penicillin_NN ,_, streptomycin_NN and_CC 10_CD %_NN fetal_JJ bovine_JJ serum_NN ._.
          Cells_NNP were_VBD grown_VBN in_IN a_DT 37_CD °_NN C_NNP incubator_NN in_IN the_DT presence_NN of_IN
          5_CD %_NN carbon_NN dioxide_NN ._. PBMCs_NNP (_( except_IN the_DT activation_NN time_NN
          course_NN )_) and_CC T_NN cells_NNS were_VBD stimulated_VBN for_IN 3_CD h_NN with_IN phorbol_NN
          ester_NN (_( 50_CD ng_NN /_NN ml_NN )_) and_CC ionomycin_NN (_( 1_CD ._. 5_LS μM_NN )_) ._. B_NN cell_NN lines_NNS
          were_VBD stimulated_VBN with_IN anti-_NN IgM_NNP antibody_NN (_( 50_CD μg_NN /_NN ml_NN )_) ._.
          Monocytes_NNP were_VBD stimulated_VBN for_IN 3_CD h_NN with_IN LPS_NNP (_( 0_CD ._. 2_LS μg_NN /_NN ml_NN )_) ._.
          CLL_NNP samples_NNS and_CC cell_NN lines_NNS used_VBN for_IN clustering_VBG in_IN Figure_NN
          4_CD awere_NN prepared_VBD according_VBG to_TO Alizadeh_NNP et_CC al_NN ._. [_NN 1_CD ]_NN ._. For_IN
          all_DT experiments_NNS ,_, 1_CD μM_NN flavopiridol_NN was_VBD used_VBN (_( except_IN the_DT
          titration_NN experiment_NN in_IN Figure_NN 1_CD a_DT )_) ._. PBMCs_NNP were_VBD first_RB
          activated_VBN at_IN 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN ml_NN with_IN PI_NNP for_IN 3_CD h_NN before_IN
          flavopiridol_NN treatment_NN ._. The_DT activation_NN of_IN the_DT PBMCs_NNP by_IN PI_NNP
          treatment_NN was_VBD confirmed_VBN by_IN FACS_NNP analysis_NN of_IN CD_NNP 69_CD and_CC CD_NNP 44_CD
          expression_NN ._.
        
        
          MTT_NNP assays_NNS
          MTT_NNP assays_NNS were_VBD done_VBN as_IN described_VBN [_NN 37_CD ]_NN ._. In_IN brief_JJ ,_,
          OCI-Ly_NNP 3_CD cells_NNS grown_VBN in_IN 96_CD -_: well_RB plates_NNS were_VBD treated_VBN with_IN
          increasing_VBG concentration_NN of_IN flavopiridol_NN (_( 0_CD to_TO 2_CD μM_NN )_) for_IN
          8_CD ,_, 24_CD or_CC 48_CD h_NN ._. MTT_NNP was_VBD added_VBN to_TO the_DT cells_NNS 2_CD h_NN before_IN
          harvesting_NN ._. Cells_NNP were_VBD lysed_JJ completely_RB in_IN isopropanol_NN
          with_IN 1_CD %_NN hydrochloric_JJ acid_NN ._. The_DT plate_NN was_VBD read_VBN with_IN a_DT
          96_CD -_: well_RB spectrometer_NN using_VBG a_DT 570_CD -_: nm_NN filter_NN ._. The_DT
          background_NN was_VBD subtracted_VBN using_VBG a_DT dual-wavelength_JJ setting_NN
          of_IN 570_CD and_CC 630_CD nm_NN ._.
        
        
          Microarray_NNP analysis_NN and_CC northern_JJ blotting_VBG
          Microarray_NNP analysis_NN was_VBD performed_VBN as_IN described_VBN [_NN 38_CD ]_NN ._.
          Total_NNP RNA_NNP was_VBD prepared_VBN using_VBG Trizol_NNP reagent_NN (_( Gibco_NNP BRL_NNP )_)
          according_VBG to_TO the_DT manufacturer_NN 's_POS instruction_NN ._. For_IN each_DT
          sample_NN ,_, 40_CD μg_NN of_IN total_JJ RNA_NNP was_VBD used_VBN for_IN the_DT labeling_VBG
          reaction_NN ._. All_DT primary_JJ microarray_NN data_NNS are_VBP available_JJ at_IN
          our_PRP$ website_NN [_NN 39_CD ]_NN ._.
          Ten_CD micrograms_NNS of_IN total_JJ RNA_NNP were_VBD used_VBN for_IN northern_JJ
          blot_NN analysis_NN ._. The_DT probes_NNS were_VBD prepared_VBN from_IN PCR_NNP
          amplification_NN of_IN the_DT cDNA_NN clones_NNS used_VBN for_IN printing_VBG the_DT
          Lymphochip_NNP ._.
        
        
          Data_NNP analysis_NN
          The_DT raw_JJ data_NN from_IN each_DT cDNA_NN array_NN were_VBD normalized_JJ as_IN
          described_VBN [_NN 38_CD ]_NN ._. Data_NNP extracted_VBD must_MD fulfill_VB the_DT
          following_VBG criteria_NNS ._. Spot_NNP size_NN must_MD be_VB >_NN 25_CD μm_NN and_CC
          expression_NN levels_NNS for_IN all_DT flavopiridol_NN studies_NNS must_MD be_VB
          >_NN 500_CD relative_JJ fluorescent_NN units_NNS (_( RFU_NNP )_) for_IN the_DT Cy_NNP 3_CD
          channel_NN ,_, and_CC >_NN 0_CD RFU_NNP for_IN the_DT Cy_NNP 5_CD channel_NN ;_: PBMC_NNP
          induction_NN studies_NNS :_: >_NN 50_CD RFU_NNP for_IN both_DT channels_NNS ._.
          For_IN the_DT half-life_NN studies_NNS in_IN Figures_NNS 2_CD ,_, 4_CD ,_, 5_CD ,_, the_DT
          array_NN elements_NNS (_( genes_NNS )_) were_VBD selected_VBN for_IN each_DT of_IN the_DT
          indicated_VBN time_NN points_NNS (_( Figure_NN 7_CD ,_, X_NNP h_NN for_IN example_NN )_) on_IN the_DT
          basis_NN of_IN three_CD criteria_NNS ._. First_LS ,_, the_DT mRNA_NN abundance_NN at_IN X_NNP
          h_NN ,_, as_IN measured_VBN by_IN the_DT ratio_NN of_IN the_DT array_NN element_NN
          (_( Cy_NNP 5_CD /_NN Cy_NNP 3_LS )_) must_MD have_VB decreased_VBN by_IN at_IN least_JJS twofold_NN ._.
          Second_JJ ,_, the_DT average_NN of_IN the_DT geometric_JJ means_NNS for_IN the_DT array_NN
          element_NN at_IN the_DT later_JJ time_NN points_NNS (_( for_IN example_NN ,_, Z_NNP 1_CD ,_, Z_NNP 2_CD ,_,
          and_CC Z_NNP 3_LS )_) must_MD be_VB less_JJR than_IN the_DT twofold_NN decrease_NN of_IN that_DT
          element_NN at_IN the_DT indicated_VBN time_NN point_NN ._. Third_NNP ,_, the_DT average_NN
          of_IN the_DT geometric_JJ means_NNS for_IN previous_JJ time_NN points_NNS (_( for_IN
          example_NN ,_, Y_NNP 1_CD and_CC Y_NNP 2_LS )_) must_MD be_VB greater_JJR than_IN the_DT twofold_NN
          decrease_NN of_IN that_DT element_NN at_IN the_DT indicated_VBN time_NN point_NN ._.
          The_DT expression_NN data_NN for_IN array_NN elements_NNS representing_VBG
          the_DT same_JJ gene_NN were_VBD averaged_VBN ._. Hierarchical_NNP clustering_VBG was_VBD
          performed_VBN using_VBG Cluster_NNP software_NN and_CC visualized_JJ using_VBG the_DT
          Tree_NN View_NNP software_NN [_NN 40_CD ]_NN ._.
        
        
          ARE-mRNA_NNP database_NN
          The_DT accession_NN numbers_NNS of_IN transcripts_NNS with_IN one_CD to_TO five_CD
          copies_NNS of_IN AUUUA_NNP were_VBD downloaded_JJ from_IN the_DT ARE-mRNA_NNP
          database_NN [_NN 41_CD ]_NN ._. These_DT transcripts_NNS were_VBD categorized_VBN by_IN
          their_PRP$ half-lives_JJ according_VBG to_TO the_DT PBMC_NNP database_NN ._.
        
        
          Mathematical_NNP analysis_NN of_IN mRNA_NN half-lives_JJ
          A_DT first-order_JJ kinetic_JJ model_NN would_MD imply_VB that_IN the_DT
          log-ratio_JJ of_IN Cy_NNP 5_CD to_TO Cy_NNP 3_CD would_MD decrease_VB linearly_RB with_IN
          time_NN ._. For_IN each_DT gene_NN ,_, we_PRP fitted_JJ a_DT linear_JJ regression_NN model_NN
          of_IN the_DT log-ratios_JJ to_TO the_DT time_NN points_NNS ,_, where_WRB the_DT model_NN
          included_VBD a_DT separate_JJ intercept_NN and_CC coefficient_NN term_NN for_IN
          each_DT of_IN the_DT three_CD drugs_NNS :_:
          log_VB 
          2_CD (_( Cy_NNP 5_CD /_NN Cy_NNP 3_LS )_) =_SYM (_( α_NN 
          Flav_NNP +_NN β_NN 
          Flav_NNP 
          t_NN )_) *_NN I_PRP 
          [_NN Flav_NNP ]_NN +_NN (_( α_NN 
          ActD_NNP +_NN β_NN 
          ActD_NNP 
          t_NN )_) *_NN I_PRP 
          [_NN ActD_NNP ]_NN +_NN (_( α_NN 
          DRB_NNP +_NN β_NN 
          DRB_NNP 
          t_NN )_) *_NN I_PRP 
          [_NN DRB_NNP ]_NN ,_,
          where_WRB 
          t_NN denotes_NNS the_DT time_NN in_IN hours_NNS ;_: I_PRP 
          [_NN ._. ]_NN denotes_NNS an_DT indicator_NN function_NN for_IN
          the_DT treatment_NN drug_NN ,_, taking_VBG the_DT values_NNS 0_CD or_CC 1_CD ,_, depending_VBG
          on_IN whether_IN or_CC not_RB that_DT treatment_NN drug_NN was_VBD used_VBN for_IN the_DT
          Cy_NNP 5_CD measurement_NN of_IN that_DT log-ratio_JJ ;_: and_CC α_NN 
          Flav_NNP ,_, β_NN 
          Flav_NNP ,_, α_NN 
          ActD_NNP ,_, β_NN 
          ActD_NNP ,_, α_NN 
          DRB_NNP ,_, and_CC β_NN 
          DRB_NNP are_VBP model_NN parameters_NNS to_TO be_VB
          estimated_VBN ._.
          Although_IN each_DT drug_NN was_VBD allowed_VBN to_TO have_VB a_DT distinct_JJ
          first-order_JJ degradation_NN rate_NN in_IN the_DT model_NN ,_, the_DT three_CD
          drugs_NNS were_VBD assumed_VBN to_TO have_VB identical_JJ error_NN distributions_NNS
          in_IN their_PRP$ assay_NN variability_NN ._. The_DT mRNA_NN half-life_NN for_IN each_DT
          drug_NN treatment_NN was_VBD computed_JJ as_IN the_DT negative_NN of_IN the_DT
          inverse_NN of_IN the_DT coefficient_NN for_IN each_DT drug_NN :_:
          
          t_NN 
          Flav_NNP =_SYM -_: 1_CD /_NN β_NN 
          Flav_NNP ,_, 
          t_NN 
          ActD_NNP =_SYM -_: 1_CD /_NN β_NN 
          ActD_NNP ,_, 
          t_NN 
          DRB_NNP =_SYM -_: 1_CD /_NN β_NN 
          DRB_NNP ._.
        
        
          Statistical_NNP analysis_NN
          The_DT following_VBG test_NN [_NN 42_CD ]_NN ,_, was_VBD used_VBN to_TO evaluate_VB whether_IN
          the_DT proportion_NN of_IN induced_VBN genes_NNS with_IN half-life_NN less_JJR than_IN
          2_CD h_NN is_VBZ statistically_RB different_JJ from_IN the_DT proportion_NN of_IN not_RB
          induced_VBN genes_NNS with_IN half-life_NN less_JJR than_IN 2_CD h_NN ,_, for_IN both_DT the_DT
          OCI-Ly_NNP 3_CD (_( Figure_NN 4_CD c_SYM )_) and_CC PBMC_NNP (_( Figure_NN 5_CD a_DT )_) :_:
          
          z_SYM =_SYM (_( |_NN 
          p_NN 
          2_CD -_: 
          p_NN 
          1_CD |_NN -_: 1_CD /_NN 2_CD *_NN (_( 1_CD /_NN 
          n_NN 
          1_CD +_NN 1_CD /_NN 
          n_NN 
          2_LS )_) )_) /_NN (_( 
          p_NN *_NN 
          q_NN *_NN (_( 1_CD /_NN 
          n_NN 
          1_CD +_NN 1_CD /_NN 
          n_NN 
          2_LS )_) )_) 1_CD /_NN 2_CD ,_,
          where_WRB 
          n_NN 
          1_CD =_SYM number_NN of_IN the_DT induced_VBN genes_NNS ,_, 
          n_NN 
          2_CD =_SYM number_NN of_IN the_DT not_RB induced_VBN genes_NNS ,_, 
          p_NN 
          1_CD =_SYM proportion_NN of_IN induced_VBN genes_NNS with_IN
          half-life_NN less_JJR than_IN 2_CD h_NN ,_, 
          p_NN 
          2_CD =_SYM proportion_NN of_IN not-induced_JJ genes_NNS
          with_IN half-life_NN less_JJR than_IN 2_CD h_NN ,_, 
          p_NN =_SYM overall_JJ proportion_NN of_IN genes_NNS
          with_IN half-life_NN less_JJR than_IN 2_CD hours_NNS ,_, and_CC 
          q_NN =_SYM 1_CD -_: 
          p_NN ._.
        
      
      
        Additional_JJ data_NNS files_NNS
        The_DT following_VBG additional_JJ data_NNS files_NNS containing_VBG the_DT
        primary_JJ data_NN for_IN the_DT figures_NNS are_VBP included_VBN with_IN this_DT
        article_NN :_: Figure_NN 1_CD a_DT ,_, flavopiridol_NN titration_NN (_( Excel_NNP csv_NN
        file_NN )_) ;_: Figure_NN 1_CD c_SYM ,_, Cdk_NNP inhibitors_NNS (_( Excel_NNP csv_NN file_NN )_) ;_: Figure_NN
        2_CD a_DT ,_, flavopiridol_NN ,_, actinomycin_NN D_NNP and_CC DRB_NNP (_( Excel_NNP csv_NN file_NN )_) ;_:
        Figure_NN 3_CD ,_, half-lives_JJ of_IN well-measured_JJ genes_NNS (_( Excel_NNP csv_NN
        file_NN )_) ;_: Figure_NN 4_CD a_DT ,_, proliferation_NN genes_NNS (_( Excel_NNP csv_NN file_NN )_) ;_:
        Figure_NN 4_CD b_SYM ,_, anti-apoptotic_JJ genes_NNS (_( Excel_NNP csv_NN file_NN )_) ;_: Figure_NN
        4_CD d_SYM ,_, induced_VBN genes_NNS in_IN OCI_NNP -_: Ly_NNP 3_CD cells_NNS (_( Excel_NNP csv_NN file_NN )_) ;_:
        Figure_NN 5_CD c_SYM ,_, highly_RB induced_VBN genes_NNS in_IN PBMC_NNP (_( Excel_NNP csv_NN file_NN )_) ;_:
        Figure_NN 5_CD d_SYM ,_, highly_RB induced_VBN chemokines_NNS ,_, cytokines_NNS and_CC their_PRP$
        receptors_NNS (_( Excel_NNP csv_NN file_NN )_) ._.
        Additional_JJ data_NNS file_VBP 1_CD
        Flavopiridol_NNP titration_NN
        Flavopiridol_NNP titration_NN
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 2_CD
        Cdk_NNP inhibitors_NNS
        Cdk_NNP inhibitors_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 3_CD
        Flavopiridol_NNP ,_, actinomycin_NN D_NNP and_CC DRB_NNP
        Flavopiridol_NNP ,_, actinomycin_NN D_NNP and_CC DRB_NNP
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 4_CD
        Half-lives_NNP of_IN well-measured_JJ genes_NNS
        Half-lives_NNP of_IN well-measured_JJ genes_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 5_CD
        Proliferation_NNP genes_NNS
        Proliferation_NNP genes_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 6_CD
        Anti-apoptotic_NNP genes_NNS
        Anti-apoptotic_NNP genes_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 7_CD
        Induced_NNP genes_NNS in_IN OCI_NNP -_: Ly_NNP 3_CD cells_NNS
        Induced_NNP genes_NNS in_IN OCI_NNP -_: Ly_NNP 3_CD cells_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 8_CD
        Highly_NNP induced_VBD genes_NNS in_IN PBMC_NNP
        Highly_NNP induced_VBD genes_NNS in_IN PBMC_NNP
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
        Additional_JJ data_NNS file_VBP 9_CD
        Highly_NNP induced_VBD chemokines_NNS ,_, cytokines_NNS and_CC their_PRP$
        receptors_NNS
        Highly_NNP induced_VBD chemokines_NNS ,_, cytokines_NNS and_CC their_PRP$
        receptors_NNS
        Click_NNP here_RB for_IN additional_JJ data_NNS file_VBP
      
    
  
